SCHEMBL679393

SCHEMBL679393

CCOC(=O)c1c(C)cc(C)n(-c2ccccc2)c1=O

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
RECQL P46063 1/20 0.60
ALDH1A1 P00352 5/20 0.55
MAPT P10636 4/20 0.55
GAA P10253 2/20 0.55
KDM4E B2RXH2 5/20 0.49
HIF1A Q16665 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PDE4D Q08499 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
THRB P10828 1/20 0.47
RAB9A P51151 1/20 0.47
HSD17B10 Q99714 1/20 0.46
MAT2A P31153 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11428841 0.88 RECQL (0.62) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL680212 0.86 L3MBTL1 (0.56) MEN1KMT2ARECQLMAPTKDM4E
SCHEMBL1974627 0.83 MEN1 (0.58) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL680088 0.82 ALDH1A1 (0.54) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL31193390 0.81 ALDH1A1 (0.68) MEN1KMT2AALDH1A1MAPTGAA
SCHEMBL10003797 0.78 RECQL (0.60) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL21810468 0.78 MEN1 (0.72) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL10003890 0.77 RECQL (0.56) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL3061680 0.77 ALDH1A1 (0.57) MEN1KMT2ARECQLALDH1A1MAPT
SCHEMBL11789226 0.77 MAPT (0.60) MEN1KMT2ARECQLALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MEN1 176/4885KMT2A 1681/4885RECQL 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.